$MRTX: Mirati Therapeutics, Inc. - Common Stock

Mirati Therapeutics, Inc. (NASDAQ: MRTX) is a clinical-stage oncology company that develops novel therapeutics to address the genetic and immunological promoters of cancer. The company's lead product candidate is KRAS G12C inhibitor adagrasib (MRTX849), which is currently being evaluated in a Phase 3 clinical trial for the treatment of patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation. Adagrasib was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in April 2022 for the treatment of patients with locally advanced or metastatic NSCLC with a KRAS G12C mutation.

In addition to adagrasib, Mirati Therapeutics has a pipeline of other clinical-stage product candidates, including:

• MRTX561, a potent and selective RET inhibitor that is being evaluated in a Phase 1 clinical trial for the treatment of patients with advanced solid tumors with RET gene fusions.
• MRTX1427, a first-in-class, orally available, small-molecule ALK inhibitor with a unique mechanism of action that is being evaluated in a Phase 1 clinical trial for the treatment of patients with advanced solid tumors with ALK gene fusions.
• MRTX1133, a novel, first-in-class, orally available, small-molecule inhibitor of the PI3K/AKT/mTOR pathway that is being evaluated in a Phase 1 clinical trial for the treatment of patients with advanced solid tumors.
• Mirati Therapeutics was founded in 2013 by Christopher Paciotti, a former research scientist at Genentech, and Martin DeMasco, a former executive at Novartis. The company is headquartered in Cambridge, Massachusetts.

Mirati Therapeutics is a well-funded company with a strong pipeline of clinical-stage product candidates. The company's lead product candidate, adagrasib, has the potential to be a blockbuster drug. If adagrasib is successful, it could generate billions of dollars in revenue for Mirati Therapeutics.

The company is also well-positioned to capitalize on the growing market for precision oncology drugs. Precision oncology is a type of cancer treatment that targets specific genetic mutations that are present in a patient's cancer cells. Adagrasib is a precision oncology drug that targets the KRAS G12C mutation, which is found in approximately 10% of patients with NSCLC.

Mirati Therapeutics is a promising company with a bright future. The company has the potential to make a significant impact on the treatment of cancer.